{
  "ticker": "ANR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967687",
  "id": "02967687",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmn7kbmr6flj.pdf",
  "summary": "### Key Material Information:  \n- **Japanese Patent Grant**: GaRP product granted a standard patent in Japan (Patent No. 7700109), valid until **9 October 2040**. Follows earlier grants in Hong Kong, Australia, and the EU.  \n- **Anti-Obesity Project Progress**: Pre-clinical studies advancing to treatment phase in diet-induced obese mice. Initial results expected in ~6 months; potential extension for further cohorts. Budget: **>$350,000** allocated.  \n- **GaRP Commercialization**: Post-trial discussions ongoing after achieving safety endpoints and **statistically significant improvements** in IBS symptoms (pain severity, frequency, distension). Target market: **US$8 billion** for non-prescription GI disorders.  \n- **R&D Tax Incentive**: Application for **2024-2025 income period** registered (confirmed 8 July 2025).  \n\n*Omitted: Operational details, background on GaRP mechanism, director contacts, and disclaimers.*",
  "usage": {
    "prompt_tokens": 2372,
    "completion_tokens": 206,
    "total_tokens": 2578,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:32:56.169301"
}